StreetInsider.com News Articles

Form SCHEDULE 13G Kailera Therapeutics, Filed by: CANADA PENSION PLAN INVESTMENT BOARD

Fri, 14 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26929918.html

Form SCHEDULE 13G Kailera Therapeutics, Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26924879.html

Form 10-Q Kailera Therapeutics, For: Jun 30

Wed, 12 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260812/26913436.html

Form 8-K Kailera Therapeutics, For: Aug 12

Wed, 12 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260812/26913254.html

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Wed, 12 Aug 2026 16:05:00 -0400

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027
Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027
Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership
Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028

WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Wed, 12 Aug 2026 16:05:00 -0400

IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027
Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, data anticipated in mid-2027
Expanded executive team to strengthen technical operations capabilities and corporate affairs leadership
Cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028

Kailera Therapeutics names Nur Nicholson as chief technology officer

Tue, 11 Aug 2026 07:00:45 -0400

Kailera Therapeutics, Inc. (Nasdaq: KLRA) announced the appointment of Nur Nicholson as chief technology officer, effective Aug. 31, 2026.

Nicholson brings nearly three decades of experience in technical operations, manufacturing, quality, and supply chain across the pharmaceutical and biotechnology industries. She previously served as chief technical operations officer at Apellis Pharmaceuticals, where she led the company's transition from a clinical-stage organization to a commercial-scale enterprise.

Prior to Apellis, Nicholson held the role of head of global supply chain and vice president of North American business operations at Galderma, overseeing supply chain operations for a $10 billion dermatology and aesthetics organization active in

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

Tue, 11 Aug 2026 07:00:00 -0400

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization

WALTHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Nur Nicholson as Chief Technology Officer, effective August 31, 2026.

“We are excited to welcome Nur as an executive at such a pivotal moment for Kailera,” said Ron Renaud, President and Chief Executive Officer of Kailera. “As we advance ribupatide injection through global Phase 3 trials, look

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

Tue, 11 Aug 2026 07:00:00 -0400

Veteran technical operations executive to lead manufacturing and supply chain strategy as company advances late-stage obesity pipeline toward commercialization

Form SCHEDULE 13G Kailera Therapeutics, Filed by: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869500.html

Form 4 Kailera Therapeutics, For: Jul 06 Filed by: Tregoning Kathleen

Wed, 08 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260708/26747819.html

Form 3 Kailera Therapeutics, For: Jun 29 Filed by: Tregoning Kathleen

Wed, 08 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260708/26747738.html

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer